MDDI Online is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

What We Learned about 7 Standout Companies at JP Morgan

Each year the J.P. Morgan Healthcare Conference serves as the start of medtech’s season. Now that it has ended, here are 7 key things we learned about companies presenting during the event.

  • 7 Key Takeways from JP Morgan

    The 4-day event known as the 37th annual JP Morgan Healthcare conference has drawn to a close. The meeting usually accomplishes two objectives. First, it’s a look back at the previous year to see how each presenting company actually fared. Second, it’s a look ahead to see how each individual company could perform. Here are seven things we learned about companies at this year’s J.P. Morgan Conference.

  • Dexcom Continues to Silence the Doubters With Hard Numbers

    There have been countless think pieces, numerous articles, and commentary spelling doom for Dexcom due to the increasing competition in the continuous glucose monitoring market. However, Dexcom continues to shine despite the looming competition and at J.P. Morgan, the San Diego-based company said it earned $1.025 billion in 2018, which represents a 43% growth in sales, when compared to 2017.


  • Boston Scientific Really Was That Company in 2018

    Boston Scientific, MDDI Editor’s Choice for Medtech Company of the Year,  reported both preliminary fourth quarter and full-year results that beat Wall Street Estimates during the J.P. Morgan Healthcare Conference. At the start of 2018, the Marlborough, MA came out swinging and began a buying spree that lasted all year long.  Michael Mahoney, Boston Scientific’s CEO said, “what I’m most proud of in 2018 - similar to previous years -  is that most of our businesses grew faster than in their peer group.”


  • Zimmer Biomet’s Comeback Story is a Work in Progress

    Supply efficiency; additional of key talent; new product introductions; and changing the way business is done in orthopedics are some of the major elements Zimmer Biomet is focused on said, its CEO Bryan Hanson. One of the big changes the company will undergo is looking at its various partnerships (i.e. Apple) and work in segments such as robotics; to create a strong ecosystem. “We’re not just a company that’s going to focus on launching products, we’re going to focus on the unique ecosystem that we can uniquely bring to the table,” Hansen said. In April of 2018, Hanson said it would take about two years to turn Zimmer Biomet. He noted the company suffered from gaps in demand planning, portfolio management, resource allocation processes, and a lack of manufacturing automation.

  • Guardant’s Lunar Gambit

    This might fall under the category of important news that occurred during the same time as the JP Morgan Healthcare Conference, but its significant nonetheless. Guardant Health has been on a roll lately and launched the Lunar Assay earlier this week.  The Redwood City, CA-based company’s assay, was developed under the LUNAR program for early-stage detection and recurrence monitoring. It is based on biological insights from more than 80,000 cancer patients tested with Guardant360, the a comprehensive liquid biopsy test, as well as learnings from whole-genome sequencing liquid biopsy data.  Guardant is fresh off raising $238 million in an initial public offering. 


  • Glaukos Is Set To Totally Dominate The MIGS Market

    Glaukos stepped into the J.P. Morgan Healthcare Conference armed with updates on a cadre of its products. The San Clemente, CA-based company operates in the micro-invasive glaucoma surgical (MIGS)  space. What is so surprising is that Glaukos has taken time to really refine and come up with several solutions for treating glaucoma. In addition, the very fabric of the company itself is changing. No longer just a medtech company – Glaukos is now a hybrid surgical, pharmaceutical, and device company.

  • Hologic is Writing its Next Chapter

    Hologic has transformed itself in the last few years. The Marlborough, MA-based company has improved its balance sheet and is beginning to find its footing with its Cynosure acquisition. In early 2018, Cynosure sales lagged, which caused concern for investors. But sales for the overall company remained strong. “We broke the historical boom/bust cycle and ultimately reshaped our balance sheet,” Steve MacMillan, chairman, president, and CEO of Hologic said. It was only a few months ago when an investor came in and said you have a strong balance sheet. I hadn’t thought about it because I was still so focused on where we came from.”


  • Edwards Only Has One Focus and That's a Good Thing.

    Edwards Lifescience’s CEO, Michael Mussallem made it clear to point out that the company had only one focus, and that’s structural heart disease in critically ill patients. The Irvine, CA-based company isn't following in the steps of other firms its size and doesn't intend to stray from this philosophy. The company's technologies center mostly around Transcatheter aortic valve replacement (TAVR) procedures. Recently, the company received a nod from FDA for the Sapien 3 Ultra Valve. “We think there are so many unmet needs within that group that we have lots of work to do for a very longtime to be successful,” Mussallem said.


Filed Under
500 characters remaining